Waging Peace.
Fighting Disease.
Building Hope.

Fighting Disease:  Brazil


Eliminating Onchocerciasis from the Americas

Current status: Transmission ongoing

Brazil's last remaining transmission zone for onchocerciasis, also known as river blindness, is the Amazonas focus, a densely forested area bordering Venezuela. Along with the Venezuelan South Focus, it comprises the Yanomami region, a contiguous transmission zone straddling the border. The migratory Yanomami people move fluidly from one side of the border to the other and are exposed to the parasitic disease as they travel throughout the Amazon. Providing medicine and health education in this area presents many challenges as it is remote, insecure, and highly endemic.  Consequently these two foci are the last in the Americas in which active transmission still occurs.

In 1996, the first year of mass drug administration in Brazil, 1,276 Mectizan® treatments (donated by Merck) were distributed. This was vastly short of the amount needed to treat the eligible population of 4,500 twice-yearly to prevent the onset of blindness. Between 2001 and 2013, the Brazilian mass drug administration program administered 24 semiannual treatments of Mectizan® (donated by Merck), reaching at least 85 percent of the eligible population. Consistently maintaining this level of coverage is vital to the eventual elimination of river blindness.  Surveys indicate Brazil is close to suppressing transmission in its shared part of the Yanomami region.  Quarterly treatments are being provided to 10 areas within Brazil's Amazonas focus, and prevalence of infection dropped from 14.7 percent in 2007 to 4 percent in 2012.

A strong partnership between the Brazilian and Venezuelan governments remains a crucial factor in elimination of river blindness in the shared Yanomami area. In 2014, the Brazilian and Venezuelan ministers of health signed a formal agreement to coordinate the effort towards elimination along their border. The agreement includes The Carter Center's Onchocerciasis Elimination Program for the Americas (OEPA), Merck's Mectizan® Donation Program, and the World Health Organization/Pan American Health Organization to reach this goal.


Sign Up for Email Updates

Thanks for Signing Up!

Please leave this field empty

Thanks for Staying Updated!

Now, we invite you to Get Involved
Yanomami child taking Mectizan treatment.

To eliminate and prevent river blindness, every affected person in every village, including this Yanomami child, must be reached and repeatedly treated with the medication Mectizan®. (Credit: Carter Center)